

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
 - TEXT CUT OFF AT TOP, BOTTOM OR SIDES
 - FADED TEXT
 - ILLEGIBLE TEXT
 - SKEWED/SLANTED IMAGES
 - COLORED PHOTOS
 - BLACK OR VERY BLACK AND WHITE DARK PHOTOS
 - GRAY SCALE DOCUMENTS
-

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



AH


INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : A61K 31/00, 31/05, 31/045, 31/11, 31/12, 31/56</p>	<p>A1</p>	<p>(11) International Publication Number: WO 97/03661 (43) International Publication Date: 6 February 1997 (06.02.97)</p>
<p>(21) International Application Number: PCT/US96/12146 (22) International Filing Date: 24 July 1996 (24.07.96) (30) Priority Data: 60/001,394 24 July 1995 (24.07.95) US (71) Applicant: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED [US/US]; 223 Grinter Hall, Gainesville, FL 32611 (US). (72) Inventors: SIMPKINS, James, W.; 1722 N.W. 11th Road, Gainesville, FL 32604 (US). GREEN, Patti, S.; Apartment 162, 2220 S.W. 34th Street, Gainesville, FL 32604 (US). GORDON, Katherine; 5 Parker Road, Winchester, MA 01890 (US). (74) Agents: SUNSTEIN, Bruce, D. et al.; Bromberg & Sunstein, 125 Summer Street, Boston, MA 02110-1618 (US).</p>		<p>(81) Designated States: AU, CA, JP, KR, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i></p>

(54) Title: USE OF NON-ESTROGEN POLYCYCLIC PHENOL COMPOUNDS FOR THE MANUFACTURE OF A MEDICAMENT FOR CONFERRING NEUROPROTECTION TO CELLS

(57) Abstract

The invention relates to the use of non-estrogen compounds having a terminal phenol group in a structure containing at least a second ring and having a molecular weight of less than 1000 Daltons (e.g. naphthols, phenanthrenes or steroid) for the manufacture of a medicament for conferring neuroprotection to cells in a subject.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France			UZ	Uzbekistan

5

USE OF NON-ESTROGEN POLYCYCLIC PHENOL COMPOUNDS FOR THE MANUFACTURE OF A MEDICAMENT FOR CONFERRING NEUROPROTECTION TO CELLS

10

TECHNICAL FIELD

The present invention relates to compositions and methods for protecting cells in the central nervous system of subjects from cell death and for stimulating neuronal survival in subjects with neurodegenerative conditions.

15

BACKGROUND

Pathological conditions resulting from the accelerated or ongoing death of neurons are prevalent in today's society and include chronic diseases such as Alzheimer's disease and Parkinson's disease, acute diseases such as stroke, brain cell loss that follows myocardial infarction, and acute neuronal injury associated with spinal cord trauma and head trauma. Chronic and acute neurodegenerative diseases and acute neuronal injury as well as associated mortality and morbidity are largely untreatable. The consequences of patient disability resulting from these conditions is a high cost to society of patient care as well as a significant reduction in quality of life. Effective therapeutic approaches directed to the prevention or reduction of neuron death or damage associated with the above conditions are needed. At present, the greatest challenge in the development of therapeutic agents for treating conditions in the brain resulting from neuron loss include obtaining an efficacious drug that is relatively non-toxic, suitable for use in both females and males, and which can readily access the brain across the blood-brain barrier.

Estrogen compounds have been found to protect neurons from cell death and have utility in retarding the progression of neurodegenerative diseases such as Alzheimer's disease. (Simpkins et al. WO 95/12402, Behl et al. (1995) Biochem. Biophys. Res. Commun. 216: 473-482; Bishop et al. (1994) Molecular and Cellular Neuroscience 5:

303-308; Simpkins et al. (1994) *Neurobiology of Aging* 15: s195-s197). Furthermore, Simpkins et al. WO 95/12402 has shown that alpha isomers of estrogen compounds, previously thought to be biologically inert, are effective in retarding neurodegeneration. This demonstration provided for the first time an opportunity to administer estrogen
5 therapeutically to men without associated sex-related side effects.

The mechanisms by which estrogen compounds bring about a neuroprotective effect are unknown although these compounds have been shown to have a number of different physiological and biochemical effects on neurons. For example, estrogen has been shown to stimulate the production of neurotrophic agents that in turn stimulate
10 neuronal growth. (REF) Estrogen compounds have also been found to inhibit NMDA-induced cell death in primary neuronal cultures (Bahl et al. *Biochem. Biophys. Res. Commun.* (1995) 216: 973; Goodman et al. *J. Neurochem* (1996) 66: 1836), and further to be capable of removing oxygen free radicals and inhibiting lipid peroxidation. (Droeschler et al. WO 95/13076). However, the potential effect of free radicals on neurons per se is
15 unproven. Droeschler et al. describes a cell free 'in vitro' assay systems using lipid peroxidation as an endpoint in which several estrogens as well as vitamin E were shown to have activity. Estradiol has also been reported to reduce lipid peroxidation of membranes (Niki (1987) *Chem. Phys. Lipids* 44: 227; Nakano et al. *Biochem. Biophys. Res. Comm.* (1987) 142: 919; Hall et al. *J. Cer. Blood Flow Metab.* (1991) 11: 292. Other
20 compounds including certain 21-amino steroids and a glucocorticosteroid have been found to act as anti-oxidants and have been examined for their use in spinal cord injury as well as head trauma, ischemia, and stroke. (Wilson et al. (1995) *J. Trauma* 39: 473; Levitt et al. (1994) *J. Cardiovasc. Pharmacol* 23: 136; Akhter et al. (1994) *Stroke* 25: 418).

As described above, a number of factors may be involved in neuroprotection.
25 Therapeutic agents that are selected on the basis of a single biochemical mechanism may have limited generalized utility in treating disease or trauma in patients. For example, in order to achieve an anti-oxidant effect *in vitro* using estrogen, Droeschler et al. used very high doses of estrogens. Such doses, even if effective on neurons *in vivo*, would have limited utility in treating chronic neurological conditions because of associated problems
30 of toxicity that result from prolonged use of high dosages.

It would be beneficial to identify a class of compounds that are non-sex related and have demonstrated biological efficacy in protecting neurons from cell death, where such

compounds could be used in the treatment of the chronic as well as the acute conditions caused by neurodegenerative diseases, trauma, and aging at non-toxic dosages. An understanding of the structural requirements for compositions capable of inducing neuroprotection would provide the basis for designing novel drugs that have enhanced neuroprotective properties while at the same time having reduced adverse side effects .

SUMMARY

The present invention satisfies the above stated need for a class of compounds that is effective in protecting neurons from deterioration and cell death arising from disease, trauma or aging and may be used to achieve a similar effect in male and female subjects with minimal adverse side effects.

In a preferred embodiment of the invention, a method is provided for conferring neuroprotection on a population of cells in a subject, having the steps of providing a non-estrogen compound, having a terminal phenol group in a structure containing at least a second ring having a molecular weight that is less than 1000 Daltons; and administering the compound in an effective dose to the population of cells to confer neuroprotection.

In another embodiment of the invention, a method of treating a neurodegenerative condition in a subject is provided, which includes the steps of selecting an effective dose of a compound having a terminal phenol ring having a molecular weight less than 1000D and at least one additional ring structure covalently-linked to the phenol ring; and administering the compound to the subject.

In another embodiment of the invention, the compound used in the method may have a four-ring structure, a three-ring structure or a two-ring structure where the four-ring structure may be administered at an effective dose that achieves a plasma concentration of less than 500nM. The molecular weight of the compound may be greater than 170 D.

In another embodiment of the invention, the three ring structure is a phenanthrene compound which may further be selected from the group consisting of tetrahydro-phenanthrene and a octahydrophenanthrene more particularly a phenanthrenemethanol or a phenanthrenecarboxyaldehyde.

In another embodiment of the invention, the two- ring structure may be fused and include a naphthol and naphthalene or may be a non-fused two ring structure having a

linkage group.

In an embodiment of the invention, the terminal phenol ring includes non-steroidal compounds. Embodiments of the invention utilize a compound having a phenolic A ring.

In a further embodiment of the invention, the dosage of the neuroprotective
5 compound results in a plasma concentration of less than 500nM, more particularly in the range of .02nM-500nM and more particularly in the range of 0.1nM-1nM.

DRAWINGS

These and other features of the invention will be better understood with reference
10 to the following description, appended claims, and accompanying drawings where

Figure 1 shows the effects of 3,17 β -estradiol and 3,17 β -estradiol 3-O-methyl ether on the % change in live SK-N-SH cell number at 48 hours of serum deprivation. Raw data were compared to the respective serum-free control group by analysis of
15 variance and Scheffe's F test and data were then normalized to the serum free group (=100%). *= $p < 0.05$ versus serum-free controls. Data are expressed as mean \pm SEM for 6 wells per group.

Figure 2 shows the effects of 3,17 β -estradiol, estriol, 2,3,17 β -triol (2-OH-
20 estradiol), 1,3,5(10)-estratriene-3-ol (estratriene-3-ol) and 2,3-O-methyl-estradiol, all at a concentration of 2nM, on live SK-N-SH cell number at 48 hours of serum deprivation. *= $p < 0.05$ versus serum free controls. **= $p < 0.05$ versus serum free controls and the respective 2,3-O-methyl estradiol. Data are expressed as mean \pm SEM for 5 wells/group.

Figure 3 shows the effects of 3,17 β -estradiol, estriol, and 17 α ethynyl 3,17 β -estradiol (ethynyl estradiol) and their 3-O-methyl ethers: estriol 3-O-methyl ether (estriol 3-O-ME) and ethynyl estradiol 3-O-methyl ether (ethynyl estradiol 3-O-ME), all at a concentration of 2nM, on live SK-N-SH cell number at 48 hrs of serum deprivation. *= $p < 0.05$ versus serum free controls and the respective 3-O-methyl steroid. **= $p < 0.05$
25 versus all other groups. Data are expressed as mean \pm SEM for 5 wells/group.
30

Figure 4 shows the effects of 3,17 β -estradiol, diethylstilbestrol (DES), DES mono-

O-methyl ether (DES mono-O-ME) and DES di-O-methyl ether (DES Di-O-ME) all at a concentration of 2nM, on live SK-N-SH cell number at 48 hours of serum deprivation.

*=p<0.05 versus serum free controls and DES di-O-methyl ether groups. Data are expressed as mean \pm SEM for 6 wells/group.

5

Figure 5 shows the effects of 3,17 β -estradiol, estrone, [2S-(2a,4a α , 10a β)-1,2,3,4,4a,9,10,10a-octahydro-7-hydroxy-2-methyl-2-phenanthrenemethanol (PAM), and [2S-(2a,4a α , 10a β)-1,2,3,4,4a,9,10,10a-octahydro-7-hydroxy-2-methyl-2-phenanthrenecarboxyaldehyde (PACA) at a concentration of 2nM on SK-N-SH dead cell number at 48 hrs of serum deprivation. *=p<0.05 versus serum free controls (SF). Data are expressed as mean \pm SEM for 6 wells/group.

Figure 6 shows the effects of 3,17 β -estradiol, estrone, [2S-(2a,4a α , 10a β)-1,2,3,4,4a,9,10,10a-octahydro-7-hydroxy-2-methyl-2-phenanthrenemethanol (PAM) and [2S-(2a,4a α , 10a β)-1,2,3,4,4a,9,10,10a-octahydro-7-hydroxy-2-methyl-2-phenanthrenecarboxyaldehyde (PACA) at 2nM on SK-N-SH live cell number at 48 hrs of serum deprivation. *=p<0.05 versus serum free controls (SF). Data are expressed as mean \pm SEM for 6 wells/group

Figure 6a shows the effects of [2S-(2a,4a α , 10a β)-1,2,3,4,4a,9,10,10a-octahydro-7-hydroxy-2-methyl-2-phenanthrenemethanol (PAM) at 2nM on the percent increase of live cell number over the serum free controls at 48 hrs of serum deprivation. *=p<0.05 versus serum free controls (SF). Statistical analysis was performed on raw data. Data are expressed as mean \pm SEM for 8 wells/group.

25

Figure 6b shows the effects of [2S-(2a,4a α , 10a β)-1,2,3,4,4a,9,10,10a-octahydro-7-hydroxy-2-methyl-2-phenanthrenecarboxyaldehyde (PACA) on the percent increase of live cell number over the serum free controls at 48 hrs of serum deprivation. *=p<0.05 versus serum free controls (SF). Statistical analysis was performed on raw data. Data are expressed as mean \pm SEM for 8 wells/group.

30

Figure 7 shows the effects of treatment of 3,17 β -estradiol (0.2 or 2nM) and 3,17 α -

- estradiol (2nM) on the toxicity induced by the neurotoxic fragment of the β amyloid protein ($A\beta$ 25-35) (20 μ m) on neuronal cells. SK-N-SH neurons were exposed to 3,17 β estradiol, 3,17 α -estradiol and $A\beta$ 25-35 alone or in combination. After a four-day exposure, live cell number was determined. $*=p,0.05$ versus serum free controls (SF).
- 5 Data are expressed as mean \pm SEM for 6 wells/group. Separate groups were exposed to 3,17 β -estradiol and 3,17 α -estradiol without the addition of $A\beta$. The steroid addition had no effect on cell number in the absence of insult.

Figure 8 shows the effect of treatment of ovariectomized rats with sham injection (oil) or with 3,17 β -estradiol at 100 μ g/kg body weight by subcutaneous injection, at 2 hours before occlusion of the middle cerebral artery. The maximum lesion size in brain cross sections of sacrificed animals was recorded and is shown as % of the cross sectional area of the brain. A,B,C,D and E correspond to brain sections at 7,9,11,13, and 15 mm respectively posterior to the olfactory bulb.

15

Figure 9 shows the effects of progesterone at 2nM on SK-N-SH live cell number at 48 hours of serum deprivation. Data are expressed as mean \pm SEM for 6 wells/group.

Figure 10 shows the effects of corticosterone at 2nM on SK-N-SH live cell number at 48 hours of serum deprivation. Data are expressed as mean \pm SEM for 6 wells/group.

Figure 11 shows the structures of 3-ring compounds: [2S-(2a,4a α ,10a β)]-1,2,3,4,4a,9,10,10a-octahydro-7-hydroxy-2-methyl-2-phenanthrenemethanol (PAM) and [2S-(2a,4a α ,10a β)]-1,2,3,4,4a,9,10,10a-octahydro-7-hydroxy-2-methyl-2-phenanthrenecarboxaldehyde (PACA).

Figure 12 shows the generalized core ring structures with numbered carbons (a) 4-ring structure, (b) 3-ring structure, (c) 2-ring structure (fused) (d) 2 ring structure (non-fused).

30

DETAILED DESCRIPTION

Neuroprotection is defined here and in the claims as the inhibition of progressive deterioration of neurons that leads to cell death.

A non-estrogen compound is defined here and in the claims as a compound, other
5 than an estrogen compound, described in the 11 th Edition of "Steroids" from Steraloids Inc., Wilton, N.H.

A phenol ring is referred to as "terminal" here and in the claims, when it is the ultimate carbon ring on a molecule consisting of more than 1 carbon ring.

A steroid is defined here and in the claims as a compound having numbered
10 carbon atoms arranged in a 4-ring structure (J. American Chemical Society 82: 5525-5581 (1960) and Pure and Applied Chemistry 31: 285-322 (1972)).

"Neurodegenerative disorder" is defined here and in the claims as a disorder in which progressive loss of neurons occurs either in the peripheral nervous system or in the central nervous system. Examples of neurodegenerative disorders include: chronic
15 neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Huntington's chorea, diabetic peripheral neuropathy, multiple sclerosis, amyotrophic lateral sclerosis; aging; and acute neurodegenerative disorders including: stroke, traumatic brain injury, schizophrenia, peripheral nerve damage, hypoglycemia, spinal cord injury, epilepsy, and anoxia and hypoxia.

20 These examples are not meant to be comprehensive-but-serve-merely-as-an illustration of the term "neurodegenerative disorder."

The present invention identifies a method of neuroprotection that utilizes a novel class of neuroprotective compounds, where the class of compounds is identified according to a set of features that has here been recognized for the first time as determinative of
25 neuroprotection. This method is further suited for the treatment of neurodegenerative diseases, trauma and aging in human subjects.

The protection of neurons from severe degeneration is an important aspect of treatment for patients with acute or chronic neurodegenerative disorders, an example of chronic disease being Alzheimer's disease. For Alzheimer's patients, the method of the
30 invention may be of significant therapeutic use. Other diseases for which such a method may be effective include Parkinson's disease, Huntington's disease, AIDS Dementia, Wernicke-Korsakoff's related dementia (alcohol induced dementia), age related dementia,

age associated memory impairment, brain cell loss due to any of the following; head trauma, stroke, hypoglycemia, ischemia, anoxia, hypoxia, cerebral edema, arteriosclerosis, hematoma and epilepsy; spinal cord cell loss due to any of the conditions listed under brain cell loss; and peripheral neuropathy. Because of the observed cytoprotective
5 properties, it is suggested that one pathway of action for the polycyclic phenolic compounds is the inhibition of apoptosis.

The characteristic set of features that define the class of neuroprotective compounds include (a) the presence of two or more ring structures in the compound where the compound has a size range less than 1000 Daltons; (b) a terminal phenol ring
10 and (c) an effective dose in vivo for causing a neuroprotective effect.

The class of neuroprotective compounds described here includes (a) compounds that are characterized by two-carbon rings (Table II); (b) compounds that are characterized by three-carbon rings (Figure 11, 12); and steroids that are characterized by 4-carbon rings, (Figure 12). Neuroprotective compounds may further comprise 5-carbon rings or
15 more providing that the overall molecular weight of 1000 Daltons is not exceeded.

According to the invention, an assay has been used as disclosed in Example 1, that utilizes SK-N-SH neuronal cells under stress to determine neuroprotection by test compounds. 3,17 β -estradiol has been selected as the control, because of its previously demonstrated neuroprotective effects (Simpkins WO 95/12402). The neuroprotective
20 activity of the control compound is shown in Figure 1. It can be seen from Figure 1, that at 48 hrs of serum deprivation, the percentage of live SK-N-SH cells increases by 100% in the presence of 2nM 3,17 β -estradiol.

This invention teaches that neuroprotection can be achieved at an effective dose providing low plasma concentrations of polycyclic phenolic compounds. More
25 specifically, a neuroprotective effect can be achieved at plasma concentrations of less than 500nM and more particularly between 0.1nM and 1nM. The relatively low effective dose of neuroprotective compounds capable of causing a neuroprotective effect according to the invention, is in stark contrast with the findings of others who have tested estrogens in *in vitro* assays. For example, Droscher et al. describe an IC₅₀ of 12.8 μ M estrogen to
30 inhibit free radical oxidation in a lipid peroxidation assay. The indirect lipid peroxidation assay for cell protection used by Droscher et al. is a biochemical assay and is not comparable to the neuron cell assay used in the invention to directly measure a

cellular response. Consequently, the two assays cannot be directly compared and the results of one assay cannot be extrapolated to the other. The advantage of the neuroprotection assay used here is that live and dying cells are utilized to determine neuroprotection directly.

5 It is desirable that the amount of a neuroprotective agent to be used to treat a subject, should be within the range that is relatively non-toxic to the patient especially when the compound is used long-term. According to the invention, significant neuroprotection has been obtained in neuronal cell cultures at concentrations of 2nM (Figures 1-6) and furthermore, significant neuroprotection has been achieved in rats at
10 100µg/kg body weight. (a dose of compound at 100µg/kg body weight provides approximately 0.4nM-2nM plasma concentration of the compound. (Figure 8).

According to the neuronal cell assay described in Example 1, it has been here demonstrated that the hydroxyl group on the phenolic A ring is required for neuroprotection. Following replacement of the hydroxyl group on the terminal phenol
15 group with, for example, a methyl group, a significant loss of neuroprotective properties of the compound was observed (Figure 1-6, Tables I and II). Furthermore, compounds that normally lack a hydroxyl group on the terminal carbon ring, such as progesterone and corticosterone, show little or no neuroprotection (Figures 9 and 10). Applicants have further determined that the hydroxyl group on the terminal phenolic group may be located
20 on any available carbon in order that neuroprotection to be maintained.

It has been determined that neuroprotective compounds for use in the method of the invention require a terminal phenolic ring. These compounds may have an R group substitution on any suitable carbon on the terminal phenolic ring other than the carbon bearing the hydroxyl group and these R groups may be present in α or β isomeric
25 configurations. Furthermore, phenol on its own is not neuroprotective nor are straight chain substitution of phenolic compounds (Table III). However, a compound having a terminal phenolic ring and at least one other carbon ring is neuroprotective. For example, the non-fused two- ring structure, diethylstilbestrol, has demonstrated neuroprotective properties according to the invention (Table II, Figure 4). This compound has a terminal
30 phenolic ring structure that is associated with a second phenolic ring via a linkage group. Removal of the hydroxyl group on the terminal phenolic ring results in a loss of neuroprotective activity.

Furthermore, compounds that are non-steroidal and have a terminal phenolic ring and at least two additional carbon ring structures include three-ring compounds (Figures 11, 12) such as exemplified by [2S-(2a,4a α ,10a β)]-1,2,3,4,4a,9,10,10a-octahydro-7hydroxy-2-methyl-2-phenanthrenemethanol (PAM) and [2S-(2a, 4a α , 10 a β)]-1,2,3,4,4a,9,10,10a-octahydro-7hydroxy-2-methyl-2-phenanthrenecarboxyaldehyde (PACA) have been demonstrated to have a neuroprotective effect (see Figure 5 and 6, 6a and 6b). The structure of these compounds are shown in Figure 12. Two nanomolar concentrations of either PAM or PACA were found to permit an increase in neuron cell survival of about 15%. Compounds having a terminal phenolic ring and at least three additional carbon rings have been shown to have a neuroprotective effect as exemplified by 3,17 β -estradiol. (Figure 1). The upper size limit of a compound of the invention that is neuroprotective and has a terminal phenolic ring depends not so much on the number of carbon rings in the structure but rather whether the compound is of a sufficiently small size to permit crossing of the blood brain barrier.

The recommended route of administration of the neuroprotective compound includes oral, intramuscular, transdermal, buccal, intravenous and subcutaneous. Methods of administering the compound of the invention may be by dose or by controlled release vehicles.

The preferred embodiment of the invention includes a compound having a terminal phenolic ring and at least a second carbon ring. In addition to these required structures, the compound may have a number of R groups attached to any available site on the phenolic ring or elsewhere providing that the phenolic structure of the terminal ring is maintained. These R-groups may be selected from inorganic or organic atoms or molecules. Below, examples of a number of different types of R groups have been provided although the invention is not limited by these examples.

(a) The R group may include any inorganic R group including any of a halogen, an amide, a sulfate, a nitrate, fluoro, chloro, or bromo groups. Additionally, R groups selected from sodium, potassium and /or ammonium salts may be attached to the alpha or beta positions to replace hydrogen on any available carbon in the structure. The R-group may be organic or may include a mixture of organic molecules and ions. Organic R groups may include alkanes, alkenes or alkynes containing up to six carbons in a linear or branched array. For example, additional R group substituents may include methyl, ethyl,

propyl, butyl, pentyl, hexyl, heptyl, dimethyl, isobutyl, isopentyl, tert-butyl, sec-butyl, isobutyl, methylpentyl, neopentyl, isohexyl, hexenyl, hexadiene, 1,3-hexadiene-5-yne, vinyl, allyl, isopropenyl, ethynyl, ethylidene, vinylidene, isopropylidene; methylene, sulfate, mercapto, methylthio, ethylthio, propylthio, methylsulfinyl, methylsulfonyl, 5 thiohexanyl, thiobenyl, thiopenol, thiocyanato, sulfoethylamide, thionitrosyl, thiophosphoryl, p-toluenesulfonate, amino, imino, cyano, carbamoyl, acetamido, hydroxyamino, nitroso, nitro, cyanato, selecyanato, arccosine, pyridinium, hydrazide, semicarbazone, carboxymethylamide, oxime, hydrazone, sulfurtrimethylammonium, semicarbazone, o-carboxymethyloxime, aldehyde hemiacetate, methylether, ethylether, 10 propylether, butylether, benzylether, methylcarbonate, carboxylate, acetate, chloroacetate, trimethylacetate, cyclopentylpropionate, propionate, phenylpropionate, carboxylic acid methylether, formate, benzoate, butyrate, caprylate, cinnamate, decylate, heptylate, enanthate, glucosiduronate, succinate, hemisuccinate, palmitate, nonanoate, stearate, tosylate, valerate, valproate, decanoate, hexahydrobenzoate, laurate, myristate, phthalate, 15 hydroxyl, ethyleneketal, diethyleneketal, formate, chloroformate, formyl, dichloroacetate, keto, difluoroacetate, ethoxycarbonyl, trichloroformate, hydroxymethylene, epoxy, peroxy, dimethyl ketal, acetone, cyclohexyl, benzyl, phenyl, diphenyl, benzylidene, and cyclopropyl groups. R groups may be attached to any of the constituent rings to form a pyridine, pyriazine, pyrimidine, or v-triazine. Additional R group substituents may 20 include any of the six member or five member-rings-itemized in section b below.

(b) Any compound having in addition to the phenol A ring, a heterocyclic carbon ring which may be an aromatic or non-aromatic phenolic ring with any of the substitutions described in (a) above and further may be selected from for example, one or more of the following structures- phenanthrene, naphthalene, naphthols, diphenyl, benzene, 25 cyclohexane, 1,2-pyran, 1,4-Pyran, 1,2-pyrone, 1,4-pyrone, 1,2-dioxin, 1,3-dioxin (dihydro form), pyridine, pyridazine, pyrimidine, pyrazine, piperazine, s-triazine, as-triazine, v-triazine, 1,2,4-oxazine, 1,3,2-oxazine, 1,3,6-oxazine (pentoxazole), 1,2,6-oxazine, 1,4-oxazine, o-isoxazine, p-isoxazine, 1,2,5-oxathiazine, 1,2,6-oxathiazine, 1,4,2-oxadiazine, 1,3,5,2-oxadiazine, morpholine (tetrahydro-p-isoxazine), any of the six 30 ringed structure listed above being a terminal group in the compound. Additionally, any of the above carbon ring structure may be linked directly or via a linkage group to any further heterocyclic aromatic or non aromatic carbon ring including: furan; thiophene

(thiofuran); pyrrole (azole); isopyrrole (isoazole); 3-isopyrrole (isoazole); pyrazole (1,2-daizole); 2-isoimidazole (1,3-isodiazole); 1,2,3-triazle; 1,2,4 triazole; 1,2-dithiole; 1,2,3-oxathiole, isoxazole (furo(a) monozole); oxazole (furo(b) monazole); thiazole; isothiazole; 1,2,3-oxadiazole; 1,2,4-oxadiazole, 1,2,5-oxadiazole, 1,3,5 oxadiazole, 1,2,3,4-oxatiazole; 1,2,3,5-oxatriazole; 1,2,3-dioxazole; 1,2,4-dioxazole; 1,3,2-dioxazole; 1,3,4-dioxazole; 1,2,5-oxathiazole; 1,3-oxathiole, cyclopentane. These compounds in turn may have associated R groups selected from section (a) or section (b) above that are substituted on the carbon ring at any of the available sites.

(c) Any compound including those listed above, that may form a cyclopentanophenanthrene ring compound and which, for example, may be selected from the group consisting of 1,3,5 (10), 6,8-estrapentaene, 1,3,5 (10), 6,8, 11-estrapentaene, 1,3,5 (10) 6,8,15-estrapentaene, 1,3,5 (10), 6,-estratetraene, 1,3,5 (10), 7-estratetraene, 1,3,5 (10)8-estratetraene, 1,3,5 (10)16-estratetraene, 1,3,5 (10)15-estratetraene, 1,3,5 (10)- estratriene, 1,3,5 (10) 15- estratriene.

(d) Any compound including precursors or derivatives selected from raloxifen, tamoxifen, androgenic compounds, and their salts where an intact phenol ring is present with a hydroxyl group present on carbons 1,2,3 and 4 of the terminal phenol ring.

(e) Any compound in the form of a prodrug, that may be metabolized to form an active polycyclic phenolic compound having neuroprotective activity.

Administration of any of the compounds of the invention may include the use of a single compound or a mixture of neuroprotective compounds.

Example 1: Assay to identify neuroprotective compounds

The cell line, SK-N-SH, a well characterized human neuroblastoma cell line, was used to test potential neuroprotective drugs. This cell line is widely considered representative of neuronal cells and an appropriate assay system for evaluation of pharmaceutical neuroprotective drugs for human diseases and injury.

SK-N-SH cells were obtained from American Type Tissue Collection (Rockville, MD). Cell cultures were grown to confluency in RPMI-1640 media supplemented with 10% Fetal Bovine Serum (FBS), 100U/ml penicillin G, and 100 mg/ml streptomycin at 37°C and under 5% CO₂ and 95% air. Media was changed three times weekly; SK-N-SH cells were backcultured every five to seven days to maintain cell lines and cells used in

the following experiments were in passages seven to twelve. The growth media were initially decanted and the cells were rinsed with 0.02% EDTA that was subsequently discarded. Another aliquot of 0.02% EDTA was then added and after a 30 min incubation of 37°C, the cells were counted on a Neubauer hemacytometer (Fisher Scientific Inc., Orlando, FL) and resuspended in appropriate media. Experiments were initiated by the backculturing of SK-N-SH at a concentration of 1.0×10^6 cells/ml in the appropriate treatment media. Cell density did not influence the response to 3,17 β -estradiol or 3,17 α -estradiol.

The neuroprotection assay involved continuous exposure of SK-N-SH cells for 48h to conditions of serum deprivation and to 2nM concentrations of each test compound. This concentration is at least 10-fold higher than that required for the neuroprotective effects of 3,17 β - and 3,17 α -estradiol. 3,17 β -estradiol was used as a control. This compound caused a dose-dependent protection of SK-N-SH cells under conditions of serum deprivation with an ED₅₀ of 0.13 nM and significant neuroprotection at the 0.2nM concentration (Fig 1). This effect was robust with the 2 nM concentration of 3,17 β -estradiol showing neuroprotection in 8 separate trials (Figures 1 to 4). Neuroprotection was determined by the magnitude of the difference in live cell number in the treated wells versus the cell number in the serum free wells. The statistical analysis was performed on the raw data in each experiment. The significance of differences among groups was determined by one way analysis of variance. Planned comparisons between groups were done using Scheffe's F-test. For all tests, $p < 0.05$ was considered significant. Following the analysis, data were normalized to the % response of the 3.17 β -estradiol group for each study using the following calculation:

$$\% \text{ Neuroprotectivity} = \frac{\text{Test cell \#} - \text{Serum-Free Cell \#}}{17\beta \text{ E2 Cell \#} - \text{Serum-Free Cell \#}}$$

Cell viability was assessed at 48 h of treatment using the Trypan Blue dye-exclusion method. At the appropriate time, cell suspensions were made by decanting media, rinsing each well with 0.2 ml, 0.02% EDTA, and incubating cells with 0.2% ml, 0.02% EDTA at 37°C for 30 min. Cells were suspended by repeated pipetting of the EDTA over the cells. One hundred μ l aliquots from each cell suspension was incubated with 100 μ l of 0.4% Trypan

Blue stain (Sigma Chemical Co.) for 5 minutes at room temperature. All suspensions were counted on a Neubauer hemacytometer within 15 minutes of addition of Trypan Blue. Two independent counts of live cells were made for each aliquot.

5 **Example 2: Comparison of the neuroprotection afforded by different four-ring and two- ring compositions.**

3,17 α -estradiol, 11,3,5(10)-estratrien-3-ol and 1,3,5(10)estra-2,3,17 β -triol (2,3-catecholestradiol) were found to be equivalent to 3,17 β -estradiol in their neuroprotectivity
10 (Figure 2, Table 1). Estrone, estriol and 17 α -ethynyl-3,17 β estradiol, while significantly neuroprotective, were less active than 3,17 β -estradiol (Figures 3 and Table II). The two-ring non-fused diethylstilbestrol (DES), was active as a neuroprotectant and retained nearly full neuroprotectivity when one, both not both, of the phenolic hydroxyl functions were replaced with an O-methyl ether function (Figure 4 and Table 2). Similarly, all
15 steroids were rendered inactive when the 3-hydroxyl group was replaced with an O-methyl ether group (Figures 1-4 and Tables I and II). a substitution that eliminates the acid, hydrophilic properties of the A ring. The 3-O methyl ether of 3,17 β -estradiol was inactive even at concentrations as high as 20nM (Fig 1). These data demonstrate that C-3 hydroxylated estratrienes are neuroprotective. A similarly positioned phenolic hydroxyl
20 group in the diphenols may serve the same function.

Two 19-carbon steroids were evaluated at a 2nM concentration for neuroprotection in the assay. The following results were obtained for live cells/ml. (mean \pm SEM X 10^3 /ml) for 5 to 6 cultures/group; Study 1: serum free controls = 94 ± 7 , testosterone = 87 ± 6 , dihydrotestosterone = 90 ± 7 , cholesterol = 65 ± 4 ; Study 2: serum free controls =
25 177 ± 18 , 3,17 β -estradiol = 329 ± 33 ($p < 0.05$ vs serum free controls), prednisolone = 187 ± 16 , 6 α -methylprednisolone = 173 ± 13 , aldosterone = 132 ± 18 . There was no neuroprotective effects of any non-phenolic steroids.

The two androgens containing a C-3 ketone, namely the partially unsaturated testosterone that lacks a phenolic A ring, and the saturated compound that lacks a
30 phenolic A ring, dihydrotestosterone, were both inactive. Similarly, all five of the 21-carbon pregnane derivatives that were tested contained a C-3 ketone function, and three Δ^4 -steroids, progesterone and aldosterone and two $\Delta^{1,4}$ -steroids, prednisolone and 6-methylprednisolone were inactive. Finally, cholesterol was tested because it has a 3-

hydroxyl function on a completely saturated A ring and was inactive. The conformational shape of the flat, phenolic ring and/or the enhanced acidity of phenols relative to cyclohexanols may be important in conferring the observed neuroprotective activity.

- In all studies, cells were cultured in RPMI-1640 media (Serum Free, SF group),
- 5 RPMI-1640 media supplemented with 10% FBS (FBS group), or RPMI-1640 media supplemented one of the following steroids at a concentration of 2nM (unless otherwise noted): 3,17 β -estradiol (1,3,5(10)-estratriene-3,17 β -diol); 3,17 α -estradiol (1,3,5(10)-estratriene-3 β ,17 α -diol); 3,17 β -estradiol 3-O-methyl ether (1,3,5(10)-estratriene-3,17 β -diol 3-O-methyl ether); 3,17 α -estradiol 3 acetate (1,3,5(10)-estratriene-3 β ,17 α -diol 3-
- 10 acetate); estrone (1,3,5(10)-estratriene-3-ol-17-one); estrone 3-O-methyl ether (1,3,5(10)-estratriene-3-ol-17-one 3-O-methyl ether); estriol (1,3,5(10)estratriene-3 β ,16 α ,17 β -triol);estriol 3-O-methyl ether (1,3,5(10)estratriene-3 β ,16 α , 17 β -triol 3-O-methyl ether); 17 α -ethynyl estradiol (1,3,5(10)-estratriene-17 α -ethynyl-3 β , 17 α -diol); ethynyl estradiol 3-O-methyl ether (1,3,5(10)-estratriene-17 α -ethynyl-3 β , 17 α -diol 3-O-methyl ether); 2-
- 15 hydroxyestradiol (1,3,5(10)estratriene-2,3,17 β -triol); 2,3-methoxyestradiol (1,3,5(10)estratrien-2,3,17 β -triol 2,3-O-methyl ether) or estratriene-3-ol (1,3,5(10)estratrien-3-ol); cortisone, progesterone, prednisolone (1,4-pregnadiene-11 β ,17,21-triol-3,20-dione); methylprednisolone (6 α -methyl-1,4-pregnadiene-11 β ,17,21-triol-3,20-dione); and aldosterone (4-pregnen-11 β ,21-diol-3,18,20-trione).
- 20 All steroids were from Steraloids, Inc., Wilton, NH and were initially dissolved at 1 mg/ml in absolute ethanol and diluted in RPMI-1640 media to a final concentration of 2 nM. To control for possible ethanol effects in the treated wells, both the serum-free media (SF group) and FBS media (FBS group) were supplemented with absolute ethanol at a concentration of 544 μ l/ml. In all studies, at least 4 and usually 6 replicate well were
- 25 treated with each media.

Example 3: Three ring structures with neuroprotective properties.

- [2S-(2a, 4a α , 10 $\alpha\beta$)]-1,2,3,4,4a,9,10, 10a-octaydro-7hydroxy-2-methyl-2-phenanthrenemethanol (PAM) and [2S-(2a, 4a α , 10 $\alpha\beta$)]-1,2,3,4,4a,9,10, 10a-octaydro-
- 30 7hydroxy-2-methyl-2-phenanthrenecarboxyaldehyde (PACA) were added to media containing SK-N-SH cells concurrent with serum deprivation. 24 or 48 hrs later, cell viability was determined by a dye production method that required the activity of

mitochondria for reduction of the dye to a colored reagent. (Goodwin et al. (1995) J. Immunol. Methods, 179: 95). Both PACA and PAM showed neuroprotective activity with peak responses at the 2nM concentration. (Figures 5a, 6a) Neuroprotective activity was similar to the positive control, 3,17 β estradiol. (Figures 5 and 6)

5








Example 4: "In vivo" dosage studies

A number of compounds were tested at doses of 100ug/kg body weight in rats injected at 2 hrs prior to occlusion of the middle cerebral artery. The injection produced plasma estradiol concentrations of 100 to 200 pg/ml (0.4 to 0.8nM) at the time of the
10 occlusion. In ovariectomized rats, maximal lesions of 25% of the brain cross-sectional area was observed. When treated with 3,17 β -estradiol, maximal lesion area was reduced by about 50%. These data demonstrate that only low nM concentrations of 3,17 β estradiol are required to protect from ischemic lesions in vivo.

15

16/1






Table I. Phenolic A Ring Requirement for the Neuroprotectivity of Estratrienes.

	Name†	% of 17 β -Estradiol Neuroprotection
	R=H 3,17 β -Estradiol	100*
	R=CH ₃ 3,17 β -Estradiol 3-O-ME	-1.5
	R=H Estratriene-3-ol	103*‡
	R=H 3,17 α -Estradiol	81*
	R=CH ₃ CO 3,17 α -Estradiol 3-acetate	-20
	R=H 2-Hydroxy-17 β -estradiol	70*
	R=CH ₃ 17 β -Estradiol 2,3-O-ME	7
	R=H Estrone	58*
	R=CH ₃ Estrone 3-O-ME	-11
	R=H Estriol	46*
	R=CH ₃ Estriol 3-O-ME	2
	R=H Ethynyl Estradiol	41*
	R=CH ₃ Mestranol	-6

*p < 0.05 vs serum-free control groups as described in Figures 1 to 4 and note 8. † = trivial name is indicated here and structural name in note 10. ‡ = No 3-O-conjugates were available for evaluation.

16/2

Table II. Neuroprotectivity of Estradiol, Phenol, Napthol and Dipenols

	Name	% of 17 β -Estradiol Neuroprotection
	3,17 β -Estradiol	100*
	Phenol	-27
	Diethylstilbestrol	74*
	Diethylstilbestrol-mono-O-ME	60*
	Diethylstilbestrol-di-O-ME	2

*p<0.05 vs serum-free control groups, as described in note 8.

TABLE III

THE EFFECTS OF BRANCHED CHAIN
SUBSTITUTED PHENOLS ON SK-N-SH LIVE
CELL NUMBERS AT 48 HOURS EXPOSURE

Treatment	Live Cell Number \pm SEM (10^3 cells/ml)
Serum free controls	203 ± 16
Butylated Hydroxyanisol	182 ± 16
Butylated hydroxytoluene	175 ± 11

We claim :

1. A method for conferring neuroprotection on a population of cells in a subject, comprising:

5 (i) providing a non-estrogen compound, having a terminal phenol group in a structure containing at least a second ring, having a molecular weight of less than 1000 Daltons; and

(ii) administering the compound in an effective dose to the population of cells so as to confer neuroprotection.

10

2. A method according to claim 1, wherein the compound comprises a four-ring structure.

3. A method according to claim 2, wherein the effective dose achieves a plasma
15 concentration of less than 500nM.

4. A method according to claim 1, wherein the compound is comprises a three-ring structure.

20 5. A method according to claim 4, wherein the three-ring compound is non-steroidal.

6. A method according to claim 1, wherein the compound comprises a two-ring structure.

25

7. A method according to claim 6, wherein the two-ring compound is non-steroidal.

8. A method according to claim 5, wherein the three compound is a phenanthrene compound.

30

9. A method according to claim 8, wherein the phenanthrene compound is selected from the group consisting of a tetrahydrophenanthrene and a octahydrophenanthrene.

10. A method according to claim 8, wherein the phenanthrene compound is selected from the group consisting of phenanthrenemethanol and phenanthrenecarboxyaldehyde.

5

11. A method according to claim 6, wherein the two ring structure is selected from the group consisting of naphthol and naphthalene.

12. A method according to claim 1, wherein the terminal phenol group has a
10 hydroxyl group on any of carbons 1-4.

13. A method according to claim 1, wherein the at least second ring structure is linked to the terminal phenol group via a linkage group.

15 14. A method according to claim 1, wherein the at least second ring structure is covalently linked to the terminal phenol group in the absence of a linkage group.

15. A method according to claim 1, wherein the effective dose achieves a plasma concentration of less than 500nM.

20

16. A method according to claim 15, wherein the effective dose achieves a plasma concentration in the range 0.02nM-500nM.

17. A method according to claim 16, wherein the effective dose achieves a plasma
25 concentration in the range 0.1nM-1nM.

18. A method according to claim 1, wherein the compound has a molecular weight that is greater than 170 Daltons.

30 19. A method according to claim 1, wherein the terminal phenol group is a phenolic A ring.

20. A method of treating a neurodegenerative disease in a subject, comprising:
- (a) preparing an effective dose of a formulation containing a compound having a terminal phenol and at least a second ring structure, having a molecular weight less than 1000 Daltons; and
- 5 (b) administering the dose to the subject.
21. A method according to claim 17, wherein the compound has a molecular weight that is greater than 170 Daltons
- 10 22. A method according to claim 20, wherein the terminal phenol is a phenolic A ring.
-

1/10




FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6




FIG. 6A

5/10




FIG. 6B

6/10




FIG. 7

7/10




FIG. 8




FIG. 9






FIG. 10

9/10



$C_{16}H_{22}O_2$
MW=246



$C_{16}H_{20}O_2$
MW=244

FIG.11

10/10




FIG. 12

INTERNATIONAL SEARCH REPORT

Int. .onal Application No
PCT/US 96/12146

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K31/00 A61K31/05 A61K31/045 A61K31/11 A61K31/12
A61K31/56

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	W0,A,87 02666 (MAGGIONI-WINTHROP S.P.A.) 7 May 1987 see page 1 see page 6, line 3 ---	1,6,7, 11-22
X	CHEMICAL ABSTRACTS, vol. 96, no. 7, 15 February 1982 Columbus, Ohio, US; abstract no. 46388, XP002014896 see abstract & ING.CHIM, vol. 63, no. 299, 1981, pages 12-24, WAEFELAER, ADOLPHE: "Structural analogs of apomorphine" ---	1-3, 12-22

	-/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- 'A' document defining the general state of the art which is not considered to be of particular relevance
- 'E' earlier document but published on or after the international filing date
- 'L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- 'O' document referring to an oral disclosure, use, exhibition or other means
- 'P' document published prior to the international filing date but later than the priority date claimed

- 'T' later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- 'X' document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- 'Y' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- '&' document member of the same patent family

Date of the actual completion of the international search

2 October 1996

Date of mailing of the international search report

05.11.96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,

Authorized officer

Teschonne D

International Application No
PCT/US 96/12146

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP,A,0 339 579 (A/S FERROSAN) 2 November 1989 see abstract ---	1,6,7, 11-22
X	WO,A,92 03049 (NEW YORK UNIVERSITY) 5 March 1992 see claims 1,2,4 ---	1,12-22
X	WO,A,92 07855 (WARNER-LAMBERT COMPANY) 14 May 1992 see page 4 see page 10 see abstract; examples 22,23,42 ---	1-3,8,9, 12-22
X	EP,A,0 659 418 (ELI LILLY AND COMPANY) 28 June 1995 see abstract see page 3, line 32 - line 48 ---	1-3, 12-22
X	EP,A,0 606 661 (F.HOFFMANN-LAROCHE AG) 20 July 1994 see page 2; example 33 ---	1-5,8,9, 12-22
X	DE,A,28 03 582 (SANDOZ PATENT GMBH) 2 August 1979 see page 22, paragraph 1; claim 1; tables 1-3 -----	1,6,7, 11-22

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 96/12146

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-8702666	07-05-87	AU-A- 6541686 JP-T- 63501869	19-05-87 28-07-88
EP-A-339579	02-11-89	AU-B- 631121 AU-A- 3336689 FI-B- 92822 JP-A- 1313461 NO-C- 173826 PT-B- 90412 US-A- 5017585 US-A- 5208232 US-A- 5158961 US-A- 5227379	19-11-92 02-11-89 30-09-94 18-12-89 09-02-94 30-09-94 21-05-91 04-05-93 27-10-92 13-07-93
WO-A-9203049	05-03-92	EP-A- 0544802 US-A- 5514714	09-06-93 07-05-96
WO-A-9207855	14-05-92	US-A- 5141934 AU-A- 9021591	25-08-92 26-05-92
EP-A-659418	28-06-95	US-A- 5552415 AU-A- 8154694 CA-A- 2138495 CN-A- 1108098 CZ-A- 9403220 HU-A- 71465 JP-A- 7215854 NO-A- 944928	03-09-96 29-06-95 22-06-95 13-09-95 13-09-95 28-11-95 15-08-95 22-06-95
EP-A-606661	20-07-94	AU-B- 668442 AU-A- 5311494 BR-A- 9400082 CA-A- 2111138 CN-A- 1097727 CZ-A- 9400086 FI-A- 940147 HU-A- 69688 JP-B- 2505978 JP-A- 6234711 NO-A- 940143	02-05-96 21-07-94 02-08-94 16-07-94 25-01-95 17-08-94 16-07-94 28-09-95 12-06-96 23-08-94 18-07-94

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 96/12146

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-606661		NZ-A- 250652	26-10-95
		PL-A- 301905	25-07-94
		US-A- 5385947	31-01-95
		ZA-A- 9400103	19-08-94

DE-A-2803582	02-08-79	NONE	
